Xencor, Inc. XNCR
34.05 USD -0.98 (-2.80%)
At closeNov 5, 2026, 4:00 PM EST
34.05 0.00 0.00%
After hours · Nov 5, 4:00 PM ET
33.96 Day range 35.81
10.38 52-week range 35.81
- YTD
- +122.40%
- 1 year
- +136.95%
News
benzinga.com Cantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price Target Cantor Fitzgerald analyst Steve Seedhouse reiterates Xencor (NASDAQ:XNCR) with a Overweight and maintains $70 price target.
zacks.com Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates Xencor (XNCR) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.08 per share a year ago.
benzinga.com Xencor Q3 EPS $0.50 Beats $(0.73) Estimate, Sales $116.520M Beat $78.587M Estimate Xencor (NASDAQ:XNCR) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $(0.73) by 168.49 percent. This is a 725 percent increase over losses of $(0.08) per…
businesswire.com Xencor Reports Third Quarter 2026 Financial Results PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today…
benzinga.com Truist Securities Maintains Buy on Xencor, Raises Price Target to $40 Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $29 to $40.
benzinga.com RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43 RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $20 to $43.
benzinga.com Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44 Wells Fargo analyst Derek Archila maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $30 to $44.- benzinga.com Wedbush Maintains Outperform on Xencor, Raises Price Target to $45 Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $30 to $45.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst Xencor reports upbeat Phase 1 kidney cancer data for XmAb819 at ESMO 2026 and selects 400 mcg/kg as the primary proposed Phase 3 study dose.
benzinga.com Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands…
benzinga.com Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.
benzinga.com Wedbush Reiterates Outperform on Xencor, Maintains $30 Price Target Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $30 price target.